NCT02091531View on ClinicalTrials.gov

Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

October 31, 2018

Study Completion Date

October 31, 2018

Conditions
Metastatic Castration-Resistant Prostate Cancer
Interventions
DRUG

MLN0128

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

Sponsors
All Listed Sponsors
collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT02091531 - Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients | Biotech Hunter | Biotech Hunter